
Release date: 2024-07-30 14:13:58 Article From: Lucius Laos Recommended: 237
Fidaxomicin is a pharmaceutical for the treatment of difficile-associated diarrhea (CDAD), indicated for adult and pediatric patients aged 6 months and older. CDAD is a gastrointestinal infection caused by Clostridium difficile, often resulting in dysbiosis of the intestinal microbiota. Fidaxomicin acts swiftly against the recalcitrant spore-forming bacterium by inhibiting bacterial RNA polymerase, exhibiting notable efficacy in the treatment of CDAD.
Prior to the commencement of Fidaxomicin therapy, patients are advised to consult with a doctor provider. A physician or pharmacist could offer tailored dietary guidance and medication counseling based on the individual circumstances of the patient.
Fidaxomicin may induce gastrointestinal reactions, such as diarrhea and nausea. Adequate hydration aids in maintaining normal intestinal function, alleviating discomfort associated with diarrhea. Patients are encouraged to minimize intake of high-fat, greasy foods, as these may impede the absorption of Fidaxomicin in the gastrointestinal tract, potentially compromising therapeutic efficacy. During treatment, patients are advised to select low-fat, bland foods.
Fidaxomicin is exclusively intended for oral administration and should not be administered via injection. The oral administration of Fidaxomicin is versatile and may be taken with food. Patients may personalize their dosing regimen according to personal dietary habits and preferences.
Patients should tailor their dietary habits in conjunction with their specific physical condition and the characteristics of the medication while administering Fidaxomicin, strictly adhering to the prescribing physician's medication guidance and dietary recommendations.
The dosage of Fidaxomicin varies depending on the patient's age and weight.
The recommended dosage for adult patients is one 200mg tablet of Fidaxomicin to be taken twice daily for a consecutive 10-day period.
Pediatric patients weighing at least 12.5 kg who can swallow tablets are prescribed the same dosage as adults. If the pediatric patient is unable to swallow tablets, an oral suspension of Fidaxomicin may be chosen. The specific dosage of the oral suspension should be determined based on the child's weight, to be administered twice daily for 10 days.
The dosage of Fidaxomicin should be individualized based on the patient's specific circumstances, and patients should strictly adhere to the physician's prescription and medication guidance to ensure the safe use of the medication.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3282024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:22025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:212025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:212025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:242025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:352025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:362025-27-11
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:3152025-13-01

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: